{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:40:06Z","timestamp":1791124806947,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"EURIPIDES","award":["201380"],"award-info":[{"award-number":["201380"]}]},{"name":"Department of Health"},{"name":"MRC"},{"name":"Wellcome Trust"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.bcp.2011.12.032","type":"journal-article","created":{"date-parts":[[2011,12,31]],"date-time":"2011-12-31T00:49:07Z","timestamp":1325292547000},"page":"805-814","source":"Crossref","is-referenced-by-count":82,"title":["Lamotrigine is a substrate for OCT1 in brain endothelial cells"],"prefix":"10.1016","volume":"83","author":[{"given":"David","family":"Dickens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Alfirevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athina","family":"Giannoudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babette","family":"Weksler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio A.","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Olivier","family":"Couraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munir","family":"Pirmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2011.12.032_bib0005","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/sj.bjp.0703337","article-title":"Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine","volume":"130","author":"Walker","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2011.12.032_bib0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0920-1211(96)00007-1","article-title":"Lamotrigine vs. phenytoin for treatment of status epilepticus: comparison in an experimental model","volume":"24","author":"Walton","year":"1996","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.bcp.2011.12.032_bib0015","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1358\/mf.2005.27.8.928299","article-title":"Neuropharmacokinetic characterization of lamotrigine after its acute administration to rats","volume":"27","author":"Castel-Branco","year":"2005","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1016\/j.bcp.2011.12.032_bib0020","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1124\/jpet.107.121525","article-title":"Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction","volume":"322","author":"Summerfield","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2011.12.032_bib0025","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/00003495-199550040-00008","article-title":"Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy","volume":"50","author":"Fitton","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2011.12.032_bib0030","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1212\/WNL.59.2.251","article-title":"Lamotrigine clearance during pregnancy","volume":"59","author":"Tran","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2011.12.032_bib0035","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/01.WNL.0000138424.33979.0C","article-title":"Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy","volume":"63","author":"Hirsch","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2011.12.032_bib0040","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1528-1157.1989.tb05309.x","article-title":"Controlled trial of lamotrigine (Lamictal) for refractory partial seizures","volume":"30","author":"Jawad","year":"1989","journal-title":"Epilepsia"},{"key":"10.1016\/j.bcp.2011.12.032_bib0045","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0920-1211(90)90077-9","article-title":"A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy","volume":"6","author":"Sander","year":"1990","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.bcp.2011.12.032_bib0050","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/0920-1211(89)90007-7","article-title":"Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy","volume":"4","author":"Binnie","year":"1989","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.bcp.2011.12.032_bib0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood\u2013brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.bcp.2011.12.032_bib0060","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1254\/fpj.122.55","article-title":"Molecular mechanisms of drug influx and efflux transport at the blood\u2013brain barrier","volume":"122","author":"Ohtsuki","year":"2003","journal-title":"Nippon Yakurigaku Zasshi"},{"key":"10.1016\/j.bcp.2011.12.032_bib0065","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1096\/fj.04-3458fje","article-title":"Blood\u2013brain barrier-specific properties of a human adult brain endothelial cell line","volume":"19","author":"Weksler","year":"2005","journal-title":"FASEB J"},{"key":"10.1016\/j.bcp.2011.12.032_bib0070","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s11095-007-9254-z","article-title":"Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications","volume":"24","author":"Koepsell","year":"2007","journal-title":"Pharm Res"},{"key":"10.1016\/j.bcp.2011.12.032_bib0075","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/leu.2009.166","article-title":"Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters","volume":"23","author":"Davies","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2011.12.032_bib0080","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1182\/blood-2007-10-116236","article-title":"Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia","volume":"112","author":"Giannoudis","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2011.12.032_bib0085","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","article-title":"A new mathematical model for relative quantification in real-time RT-PCR","volume":"29","author":"Pfaffl","year":"2001","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bcp.2011.12.032_bib0090","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.bjp.0707601","article-title":"Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells","volume":"153","author":"Martin","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2011.12.032_bib0095","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2125.2011.03941.x","article-title":"Possible drug\u2013drug interaction between quetiapine and lamotrigine\u2014evidence from a Swedish TDM database","volume":"72","author":"Andersson","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2011.12.032_bib0100","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2011.12.032_bib0105","doi-asserted-by":"crossref","first-page":"7559","DOI":"10.1021\/jm060642i","article-title":"Structure\u2013brain exposure relationships","volume":"49","author":"Hitchcock","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2011.12.032_bib0110","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1528-1157.1999.tb01990.x","article-title":"Lamotrigine concentrations in human serum, brain tissue, and tumor tissue","volume":"40","author":"Meyer","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.bcp.2011.12.032_bib0115","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2011.12.032_bib0120","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","article-title":"Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia","volume":"83","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bcp.2011.12.032_bib0125","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00210-007-0219-x","article-title":"Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1)","volume":"376","author":"Nies","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.bcp.2011.12.032_bib0130","doi-asserted-by":"crossref","first-page":"e22163","DOI":"10.1371\/journal.pone.0022163","article-title":"Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs)","volume":"6","author":"Nies","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2011.12.032_bib0135","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/clpt.2009.92","article-title":"The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin","volume":"86","author":"Tzvetkov","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bcp.2011.12.032_bib0140","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/sj.clpt.6100275","article-title":"Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics","volume":"83","author":"Shu","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bcp.2011.12.032_bib0145","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1471-4159.2010.06801.x","article-title":"Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood\u2013brain barrier and MPTP-induced dopaminergic toxicity in rodents","volume":"114","author":"Lin","year":"2010","journal-title":"J Neurochem"},{"key":"10.1016\/j.bcp.2011.12.032_bib0150","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.seizure.2007.11.023","article-title":"Lamotrigine therapeutic thresholds","volume":"17","author":"Khinchi","year":"2008","journal-title":"Seizure"},{"key":"10.1016\/j.bcp.2011.12.032_bib0155","doi-asserted-by":"crossref","first-page":"5902","DOI":"10.1073\/pnas.0730858100","article-title":"Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1","volume":"100","author":"Shu","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2011.12.032_bib0160","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.bbrc.2003.11.175","article-title":"Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions","volume":"313","author":"Sakata","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bcp.2011.12.032_bib0165","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","article-title":"In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction","volume":"34","author":"Rowland","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2011.12.032_bib0170","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2125.1992.tb04079.x","article-title":"Sodium valproate acutely inhibits lamotrigine metabolism","volume":"33","author":"Yuen","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2011.12.032_bib0175","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1474-4422(03)00483-6","article-title":"Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bcp.2011.12.032_bib0180","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s002280000146","article-title":"Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects","volume":"56","author":"Ebert","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2011.12.032_bib0185","doi-asserted-by":"crossref","first-page":"5932","DOI":"10.1021\/jm8003152","article-title":"Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1","volume":"51","author":"Ahlin","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2011.12.032_bib0190","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/00003088-200140070-00003","article-title":"Clinical pharmacokinetics of quetiapine: an atypical antipsychotic","volume":"40","author":"DeVane","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bcp.2011.12.032_bib0195","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004714-200102000-00016","article-title":"The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine","volume":"21","author":"Wong","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.bcp.2011.12.032_bib0200","first-page":"400","article-title":"Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions","volume":"23","author":"Ahlin","year":"2010","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.bcp.2011.12.032_bib0205","first-page":"17","article-title":"Lamotrigine plus quetiapine combination therapy in treatment-resistant bipolar depression","volume":"23","author":"Ahn","year":"2011","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.bcp.2011.12.032_bib0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1528-1157.1995.tb01657.x","article-title":"MDR1 gene expression in brain of patients with medically intractable epilepsy","volume":"36","author":"Tishler","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.bcp.2011.12.032_bib0215","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.neulet.2007.10.007","article-title":"Increased expression of the lysosomal protease cathepsin S in hippocampal microglia following kainate-induced seizures","volume":"429","author":"Akahoshi","year":"2007","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bcp.2011.12.032_bib0220","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/1520-6017(200104)90:4<397::AID-JPS1000>3.0.CO;2-D","article-title":"Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters","volume":"90","author":"Dresser","year":"2001","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.bcp.2011.12.032_bib0225","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.bjp.0704785","article-title":"Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3","volume":"136","author":"Hayer-Zillgen","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2011.12.032_bib0230","doi-asserted-by":"crossref","first-page":"F853","DOI":"10.1152\/ajprenal.2000.278.6.F853","article-title":"Structure of renal organic anion and cation transporters","volume":"278","author":"Burckhardt","year":"2000","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.bcp.2011.12.032_bib0235","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1124\/dmd.108.025254","article-title":"Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells","volume":"37","author":"Minematsu","year":"2009","journal-title":"Drug Metab Dispos"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295211009488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295211009488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T22:04:22Z","timestamp":1593468262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295211009488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0006295211009488"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2011.12.032","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}